Nano-lipidic formulation and therapeutic strategies for Alzheimer’s disease via intranasal route

References

• Abe, K., et al., 2020. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer’s disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer’s disease neuroimaging initiative da. Journal of the neurological sciences, 416, 116989.
   PubMed Web of Science ®Google Scholar
• Aderibigbe, B.A., 2018. In situ-based gels for nose to brain delivery for the treatment of neurological diseases. Pharmaceutics, 10 (2), 40.
   PubMed Web of Science ®Google Scholar
• Al Arifi, M.N., 2020. Evaluation of knowledge of Alzheimer disease among health university students in Riyadh, Saudi Arabia. Saudi pharmaceutical journal, 28 (8), 911–915.
   PubMed Web of Science ®Google Scholar
• Alam, M.I., et al., 2013. Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood. Drug delivery, 20 (6), 247–251.
   PubMed Web of Science ®Google Scholar
• Aminu, N., et al., 2020. The influence of nanoparticulate drug delivery systems in drug therapy. Journal of drug delivery science and technology, 60, 101961.
   Web of Science ®Google Scholar
• Anton, N., and Vandamme, T.F., 2011. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharmaceutical research, 28 (5), 978–985.
   PubMed Web of Science ®Google Scholar
• Arya, M.A., et al., 2019. Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer’s disease. Journal of drug delivery science and technology, 51, 297–309.
   Web of Science ®Google Scholar
• Arya, R.K.K., and Juyal, V., 2017. Polymer -lipid hybrid nanoparticles for brain targeting through intranasal delivery. Journal of drug delivery and therapeutics, 7 (4), 129–136.
   Google Scholar
• Bachmann, M.F., and Jennings, G.T., 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature reviews immunology, 10 (11), 787–796.
   PubMed Web of Science ®Google Scholar
• Bakr, M.M., Shukr, M.H., and ElMeshad, A.N., 2020. In situ hexosomal gel as a promising tool to ameliorate the transnasal brain delivery of vinpocetine: central composite optimization and in vivo biodistribution. Journal of pharmaceutical sciences, 109 (7), 2213–2223.
   PubMed Web of Science ®Google Scholar
• Ban, C., et al., 2020. Enhancing the oral bioavailability of curcumin using solid lipid nanoparticles. Food chemistry, 302, 125328.
   PubMed Web of Science ®Google Scholar
• Batist, G., et al., 2002. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert opinion on pharmacotherapy, 3 (12), 1739–1751.
   PubMedGoogle Scholar
• Battaglia, L., et al., 2018. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Expert opinion on drug delivery, 15 (4), 369–378.
   PubMed Web of Science ®Google Scholar
• Batzu, L., Westman, E., and Pereira, J.B., 2020. Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer's disease. Neurobiology of aging, 88, 61–70.
   PubMed Web of Science ®Google Scholar
• Bonferoni, M.C.G., et al., 2019. Nanoemulsions for “nose-to-brain” drug delivery. Pharmaceutics, 11 (2), 84.
   PubMed Web of Science ®Google Scholar
• Chatterjee, B., et al., 2019. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. International journal of pharmaceutics, 565, 258–268.
   PubMed Web of Science ®Google Scholar
• Chatzitaki, A.T., et al., 2020. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety. International journal of pharmaceutics, 589, 119776.
   PubMed Web of Science ®Google Scholar
• Citron, M., 2010. Alzheimer's disease: strategies for disease modification. Nature reviews drug discovery, 9 (5), 387–398.
   PubMed Web of Science ®Google Scholar
• Copeland, C., and Stabenfeldt, S.E., 2020. Leveraging the dynamic blood-brain barrier for central nervous system nanoparticle-based drug delivery applications. Current opinion in biomedical engineering, 14, 1–8.
   PubMedGoogle Scholar
• Corace, G., et al., 2014. Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. Journal of liposome research, 24 (4), 323–335.
   PubMed Web of Science ®Google Scholar
• Dá Mesquita, S., et al., 2016. Insights on the pathophysiology of Alzheimer's disease: the crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience and biobehavioral reviews, 68, 547–562.
   PubMed Web of Science ®Google Scholar
• Dai, T., Jiang, K., and Lu, W., 2018. Liposomes and lipid disks traverse the BBB and BBTB as intact forms as revealed by two-step Förster resonance energy transfer imaging. Acta pharmaceutica sinica. B, 8 (2), 261–271.
   PubMed Web of Science ®Google Scholar
• de Marie, S., Janknegt, R., and Bakker-Woudenberg, I.A., 1994. Clinical use of liposomal and lipid-complexed amphotericin B. The journal of antimicrobial chemotherapy, 33 (5), 907–916.
   PubMed Web of Science ®Google Scholar
• Dhas, N., and Mehta, T., 2020. Cationic biopolymer functionalized nanoparticles encapsulating lutein to attenuate oxidative stress in effective treatment of Alzheimer's disease: a non-invasive approach. International journal of pharmaceutics, 586, 119553.
   PubMed Web of Science ®Google Scholar
• dos Santos Rodrigues, B., Kanekiyo, T., and Singh, J., 2020. In vitro and in vivo characterization of CPP and transferrin modified liposomes encapsulating pDNA. Nanomedicine: nanotechnology, biology, and medicine, 28, 102225.
   PubMed Web of Science ®Google Scholar
• Doskocz, J., et al., 2020. The effect of lipid phase on liposome stability upon exposure to the mechanical stress. Biochimica et biophysica acta. Biomembranes, 1862 (9), 183361,
   PubMed Web of Science ®Google Scholar
• Dwivedi, P., Kumar Tekade, R., and Kumar Jain, N., 2013. Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in Alzheimer’s disease. Current nanoscience, 9 (1), 46–55.
   Web of Science ®Google Scholar
• E. Eleraky, N., et al., 2020. Nanostructured lipid carriers to mediate brain delivery of temazepam: design and in vivo study. Pharmaceutics, 12 (5), 451.
   PubMed Web of Science ®Google Scholar
• Eid, H.M., et al., 2019. Transfersomal nanovesicles for nose-to-brain delivery of ofloxacin for better management of bacterial meningitis: formulation, optimization by Box-Behnken design, characterization and in vivo pharmacokinetic study. Journal of drug delivery science and technology, 54, 101304.
   Web of Science ®Google Scholar
• Erdő, F., et al., 2018. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain research bulletin, 143, 155–170.
   PubMed Web of Science ®Google Scholar
• Fatouh, A.M., Elshafeey, A.H., and Abdelbary, A., 2017. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug design, development and therapy, 11, 1815–1825.
   PubMed Web of Science ®Google Scholar
• Fortuna, A., et al., 2014. Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. European journal of pharmaceutics and biopharmaceutics, 88 (1), 8–27.
   PubMed Web of Science ®Google Scholar
• Gartziandia, O., et al., 2015. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids and surfaces. B, biointerfaces, 134, 304–313.
   PubMed Web of Science ®Google Scholar
• Ghasemiyeh, P., and Mohammadi-Samani, S., 2018. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Research in pharmaceutical sciences, 13 (4), 288–303.
   PubMed Web of Science ®Google Scholar
• Giunchedi, P., Gavini, E., and Bonferoni, M.C., 2020. Nose-to-brain delivery. Pharmaceutics, 12 (2), 138.
   PubMed Web of Science ®Google Scholar
• Grabrucker, A.M., 2014. Nanoparticles as blood-brain barrier permeable CNS targeted drug delivery systems. Topics in medicinal chemistr, 10, 71–89.
   Google Scholar
• Haider, M., et al., 2020. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics, 12 (3), 288.
   PubMed Web of Science ®Google Scholar
• Haider, M.F., et al., 2018. Optimization of rivastigmine nanoemulsion for enhanced brain delivery: in-vivo and toxicity evaluation. Journal of molecular liquids, 255, 384–396.
   Web of Science ®Google Scholar
• Hao, J., et al., 2016. Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. Colloids and surfaces. B, biointerfaces, 147, 376–386.
   PubMed Web of Science ®Google Scholar
• Harilal, S., et al., 2019. Advancements in nanotherapeutics for Alzheimer's disease: current perspectives. The journal of pharmacy and pharmacology, 71 (9), 1370–1383.
   PubMed Web of Science ®Google Scholar
• Harilal, S., et al., 2020. Revisiting the blood-brain barrier: a hard nut to crack in the transportation of drug molecules. Brain research bulletin, 160, 121–140.
   PubMed Web of Science ®Google Scholar
• Hersh, D.S., et al., 2016. Evolving drug delivery strategies to overcome the blood brain barrier. Current pharmaceutical design, 22 (9), 1177–1193.
   PubMed Web of Science ®Google Scholar
• Hiemenz, J.W., and Walsh, T.J., 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clinical infectious diseases, 22 (Suppl 2), S133–S44.
   PubMed Web of Science ®Google Scholar
• Huang, M., et al., 2015. GM1-modified lipoprotein-like nanoparticle: multifunctional nanoplatform for the combination therapy of Alzheimer's disease. ACS nano, 9 (11), 10801–10816.
   PubMed Web of Science ®Google Scholar
• Huang, S., et al., 2020. Improved physicochemical properties of curcumin-loaded solid lipid nanoparticles stabilized by sodium caseinate-lactose maillard conjugate. Journal of agricultural and food chemistry, 68 (26), 7072–7081.
   PubMed Web of Science ®Google Scholar
• Ibaraki, H., et al., 2020. The effects of surface properties of liposomes on their activity against Pseudomonas aeruginosa PAO-1 biofilm. Journal of drug delivery science and technology, 57, 101754.
   Web of Science ®Google Scholar
• Imbimbo, B.P., Lombard, J., and Pomara, N., 2005. Pathophysiology of Alzheimer’s disease. Neuroimaging clinics of North America, 1 15 (4), 727–753.
   PubMed Web of Science ®Google Scholar
• Islam, S.U., et al., 2020. Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules, 25 (8), 1929.
   PubMed Web of Science ®Google Scholar
• Janknegt, R., et al., 1992. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clinical pharmacokinetics, 23 (4), 279–291.
   PubMed Web of Science ®Google Scholar
• Jiang, Y., et al., 2019. The optimization design of lactoferrin loaded hupa nanoemulsion for targeted drug transport via intranasal route. International journal of nanomedicine, 14, 9217–9234.
   PubMed Web of Science ®Google Scholar
• Jnaidi, R., Almeida, A.J., and Gonçalves, L.M., 2020. Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery systems in the treatment of glioblastoma multiforme. Pharmaceutics, 12 (9), 860.
   PubMed Web of Science ®Google Scholar
• Jojo, G.M., et al., 2019. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design. Drug development and industrial pharmacy, 45 (7), 1061–1072.
   PubMed Web of Science ®Google Scholar
• Joshi, M., and Patravale, V., 2006. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib. Drug development and industrial pharmacy, 32 (8), 911–918.
   PubMed Web of Science ®Google Scholar
• Joshi, M., and Patravale, V., 2008. Nanostructured lipid carrier (NLC) based gel of celecoxib. International journal of pharmaceutics, 346 (1–2), 124–132.
   PubMed Web of Science ®Google Scholar
• Juliano, R.L., et al., 1987a. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Molecular pharmacology, 31 (1), 1–11.
   PubMed Web of Science ®Google Scholar
• Juliano, R.L., et al., 1987b. Membrane-to-membrane transfer of lipophilic drugs used against cancer or infectious disease. Annals of the New York academy of sciences, 507, 89–103.
   PubMed Web of Science ®Google Scholar
• Kreuter, J., et al., 2002. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Journal of drug targeting, 10 (4), 317–325.
   PubMed Web of Science ®Google Scholar
• Kumar, M., et al., 2014. Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. International journal of pharmaceutics, 461 (1–2), 223–233.
   PubMed Web of Science ®Google Scholar
• Kumar, R., et al., 2020. Preparation, characterization and in vitro cytotoxicity of Fenofibrate and Nabumetone loaded solid lipid nanoparticles. Materials science & engineering. C, materials for biological applications, 106, 110184.
   PubMed Web of Science ®Google Scholar
• Lerner, E.N., Van Zanten, E.H., and Stewart, G.R., 2004. Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. Journal of drug targeting, 12 (5), 273–280.
   PubMed Web of Science ®Google Scholar
• Li, W., et al., 2012. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environmental toxicology and pharmacology, 34 (2), 272–279.
   PubMed Web of Science ®Google Scholar
• Lippens, R.J.J., 1999. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors. Pediatric hematology and oncology, 16 (2), 131–139.
   PubMed Web of Science ®Google Scholar
• Lobaina Mato, Y., 2019. Nasal route for vaccine and drug delivery: features and current opportunities. International journal of pharmaceutics, 572, 118813.
   PubMed Web of Science ®Google Scholar
• Loyse, A., et al., 2013. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. The lancet. Infectious diseases, 13 (7), 629–637.
   PubMed Web of Science ®Google Scholar
• Madane, R.G., and Mahajan, H.S., 2016. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug delivery, 23 (4), 1326–1334.
   PubMed Web of Science ®Google Scholar
• Maritim, S., Boulas, P., and Lin, Y., 2021. Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes. International journal of pharmaceutics, 592, 120051.
   PubMed Web of Science ®Google Scholar
• Martins, P.P., Smyth, H.D.C., and Cui, Z., 2019. Strategies to facilitate or block nose-to-brain drug delivery. International journal of pharmaceutics, 570, 118635.
   PubMed Web of Science ®Google Scholar
• Masjedi, M., et al., 2020. Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. The journal of pharmacy and pharmacology, 72 (10), 1341–1351.
   PubMed Web of Science ®Google Scholar
• Md, S., et al., 2015. Nanoneurotherapeutics approach intended for direct nose to brain delivery. Drug development and industrial pharmacy, 41 (12), 1922–1934.
   PubMed Web of Science ®Google Scholar
• Mischler, R., and Metcalfe, I.C., 2002. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine, 20 (Suppl 5), B17–23.
   PubMed Web of Science ®Google Scholar
• Mittal, D., et al., 2014. Insights into direct nose to brain delivery: current status and future perspective. Drug delivery, 21 (2), 75–86.
   PubMed Web of Science ®Google Scholar
• Mohamed, S., et al., 2020. Novel lipid-polymer hybrid nanoparticles incorporated in thermosensitive in situ gel for intranasal delivery of terbutaline sulphate. Journal of microencapsulation, 37 (8), 577–594.
   PubMed Web of Science ®Google Scholar
• Moura, M.C.P.A., et al., 2019. Microemulsions and nanoemulsions applied to iron ore flotation. Journal of materials research and technology, 8 (3), 978–2986.
   Google Scholar
• Muntimadugu, E., et al., 2016. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer’s disease. European journal of pharmaceutical sciences, 92, 224–234.
   PubMed Web of Science ®Google Scholar
• Narayan, R., et al., 2016. Development of risperidone liposomes for brain targeting through intranasal route. Life sciences, 163, 38–45.
   PubMed Web of Science ®Google Scholar
• Nasr, M., and Wahdan, S.A., 2019. Neuroprotective effects of novel nanosystems simultaneously loaded with vinpocetine and piracetam after intranasal administration. Life sciences, 226 (l), 117–129.
   PubMed Web of Science ®Google Scholar
• Neupane, Y.R., et al., 2014. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment. International journal of pharmaceutics, 477 (1-2), 601–612.
   PubMed Web of Science ®Google Scholar
• Northfelt, D.W., et al., 1996. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. Journal of clinical pharmacology, 36 (1), 55–63.
   PubMed Web of Science ®Google Scholar
• Oz, M., Petroianu, G., and Lorke, D.E., 2016. α7-nicotinic acetylcholine receptors: new therapeutic avenues in Alzheimer’s disease. Neuromethods, 13 (5), 613–622.
   Google Scholar
• Pardeike, J., et al., 2011. Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. International journal of pharmaceutics, 419 (1–2), 329–338.
   PubMed Web of Science ®Google Scholar
• Pashirova, T.N., et al., 2018. Mixed cationic liposomes for brain delivery of drugs by the intranasal route: the acetylcholinesterase reactivator 2-PAM as encapsulated drug model. Colloids and surfaces. B, biointerfaces, 171, 358–367.
   PubMed Web of Science ®Google Scholar
• Patel, M.R., et al., 2016. Paliperidone microemulsion for nose-to-brain targeted drug delivery system: pharmacodynamic and pharmacokinetic evaluation. Drug delivery, 23 (1), 346–354.
   PubMed Web of Science ®Google Scholar
• Patel, S., et al., 2011. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. Journal of drug targeting, 19 (6), 468–474.
   PubMed Web of Science ®Google Scholar
• Pires, P.C., and Santos, A.O., 2018. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. Journal of controlled release, 270, 89–100.
   PubMed Web of Science ®Google Scholar
• Pokharkar, V., Patil-Gadhe, A., and Palla, P., 2017. Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: in-vivo pharmacokinetic and toxicity study. Biomedicine & pharmacotherapy, 94, 150–164.
   PubMed Web of Science ®Google Scholar
• Puligundla, P., et al., 2017. Nanotechnological approaches to enhance the bioavailability and therapeutic efficacy of green tea polyphenols. Journal of functional foods, 34, 139–151.
   Web of Science ®Google Scholar
• Pyo, Y.C., et al., 2020. Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. Colloids and surfaces. B, biointerfaces, 196, 111331.
   PubMed Web of Science ®Google Scholar
• Qian, S., He, L., et al., 2018. Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. Life sciences, 207, 428–435.
   PubMed Web of Science ®Google Scholar
• Rajput, A.P., and Butani, S.B., 2019. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: formulation, optimization and in vivo characterization. Journal of drug delivery science and technology, 51, 214–233.
   Web of Science ®Google Scholar
• Robinson, R.F., and Nahata, M.C., 1999. A comparative review of conventional and lipid formulations of amphotericin B. Journal of clinical pharmacy and therapeutics, 24 (4), 249–257.
   PubMed Web of Science ®Google Scholar
• Sabir, F., Ismail, R., and Csoka, I., 2020. Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug discovery today, 25 (1), 185–194.
   PubMed Web of Science ®Google Scholar
• Salem, H.F., et al., 2019. Brain targeting of resveratrol through intranasal lipid vesicles labelled with gold nanoparticles: in vivo evaluation and bioaccumulation investigation using computed tomography and histopathological examination. Journal of drug targeting, 27 (10), 1127–1134.
   PubMed Web of Science ®Google Scholar
• Scheideler, M., Vidakovic, I., and Prassl, R., 2020. Lipid nanocarriers for microRNA delivery. Chemistry and physics of lipids, 226, 104837.
   PubMed Web of Science ®Google Scholar
• Shah, B., et al., 2015a. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. European journal of pharmaceutical sciences, 78, 54–66.
   PubMed Web of Science ®Google Scholar
• Shah, B., et al., 2016. Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: risk assessment and QbD based optimization. Journal of drug delivery science and technology, 33, 37–50.
   Web of Science ®Google Scholar
• Shah, B.M., et al., 2015b. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug delivery, 22 (7), 918–930.
   PubMed Web of Science ®Google Scholar
• Shinde, R.L., and Devarajan, P.V., 2017. Docosahexaenoic acid-mediated, targeted and sustained brain delivery of curcumin microemulsion. Drug delivery, 24 (1), 152–161.
   PubMed Web of Science ®Google Scholar
• Singh, A., et al., 2020. Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity. International journal of biological macromolecules, 149, 1198–1206.
   PubMed Web of Science ®Google Scholar
• Sintov, A.C., 2020. AmyloLipid nanovesicles: a self-assembled lipid-modified starch hybrid system constructed for direct nose-to-brain delivery of curcumin. International journal of pharmaceutics, 588, 119725.
   PubMed Web of Science ®Google Scholar
• Sonali, S, et al., 2016. RGD-TPGS decorated theranostic liposomes for brain targeted delivery. Colloids and surfaces B: Biointerfaces, 147, 129–141.
   PubMed Web of Science ®Google Scholar
• Sood, S., Jain, K., and Gowthamarajan, K., 2014. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids and Surfaces B Biointerfaces, 113, 330–337.
   PubMed Web of Science ®Google Scholar
• Teixeira, M.I., et al., 2020. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. European journal of pharmaceutics and biopharmaceutics, 149, 192–217.
   PubMed Web of Science ®Google Scholar
• Teleanu, D.M., et al., 2019. Nanomaterials for drug delivery to the central nervous system. Nanomaterials, 9 (3), 371.
   Web of Science ®Google Scholar
• Tong-Un, T., et al., 2010. Nasal administration of quercetin liposomes improves memory impairment and neurodegeneration in animal model of Alzheimer’s disease. American journal of agricultural and biological science, 5 (3), 286–293.
   Google Scholar
• Trucillo, P., and Reverchon, E., 2021. Production of PEG-coated liposomes using a continuous supercritical assisted process. The journal of supercritical fluids, 167, 105048.
   Web of Science ®Google Scholar
• Ul Islam, S., et al., 2020. Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules, 25 (8), 1929.
   PubMed Web of Science ®Google Scholar
• Urandur, S., et al., 2018. Anisamide-anchored lyotropic nano-liquid crystalline particles with AIE effect: a smart optical beacon for tumor imaging and therapy. ACS applied materials & interfaces, 10 (15), 12960–12974.
   PubMed Web of Science ®Google Scholar
• van Leeuwen, E., Hampton, M.B., and Smyth, L.C.D., 2020. Redox signalling and regulation of the blood-brain barrier. The international journal of biochemistry & cell biology, 125, 105794.
   PubMed Web of Science ®Google Scholar
• Vieira, D.B., and Gamarra, L.F., 2016. Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. International journal of nanomedicine, 11, 5381–5414.
   PubMed Web of Science ®Google Scholar
• Vishwakarma, N., et al., 2019. Lipid-based nanocarriers for lymphatic transportation. AAPS PharmSciTech, 20 (2), 83.
   PubMed Web of Science ®Google Scholar
• Wan, Y., et al., 2020. Meta-analysis of the Alzheimer’s disease human brain transcriptome and functional dissection in mouse models. Cell reports, 32 (2), 107908.
   PubMed Web of Science ®Google Scholar
• Wavikar, P., Pai, R., and Vavia, P., 2017. Nose to brain delivery of rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics. Journal of pharmaceutical sciences, 106 (12), 3613–3622.
   PubMed Web of Science ®Google Scholar
• Wavikar, P.R., and Vavia, P.R., 2015. Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery. Journal of liposome research, 25 (2), 141–149.
   PubMed Web of Science ®Google Scholar
• Weissig, V., Pettinger, T.K., and Murdock, N., 2014. Nanopharmaceuticals (part 1): products on the market. International journal of nanomedicine, 9, 4357–4373.
   PubMed Web of Science ®Google Scholar
• Wen, M.M., et al., 2017. Nanotechnology-based drug delivery systems for Alzheimer's disease management: technical, industrial, and clinical challenges. Journal of controlled release, 245, 95–107.
   PubMed Web of Science ®Google Scholar
• Wilson, B., and Geetha, K.M., 2020. Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease. Journal of controlled release, 325, 25–37.
   PubMed Web of Science ®Google Scholar
• Wu, H., et al., 2012. A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-β₂₅₋₃₅-treated rats following intranasal administration. European journal of pharmaceutics and biopharmaceutics, 80 (2), 368–378.
   PubMed Web of Science ®Google Scholar
• Wu, Y., et al., 2020. Predicting Alzheimer's disease based on survival data and longitudinally measured performance on cognitive and functional scales. Psychiatry research, 291, 113201.
   PubMed Web of Science ®Google Scholar
• Xu, Y., Wei, L., and Wang, H., 2020. Progress and perspectives on nanoplatforms for drug delivery to the brain. Journal of drug delivery science and technology, 57, 101636.
   Web of Science ®Google Scholar
• Yang, H., 2010. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharmaceutical research, 27 (9), 1759–1771.
   PubMed Web of Science ®Google Scholar
• Yang, S.J., et al., 2020. Functional linear regression model with randomly censored data: predicting conversion time to Alzheimer’s disease. Computational statistics & data analysis, 150, 107009.
   Web of Science ®Google Scholar
• Yang, Z.Z., et al., 2013. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. International journal of pharmaceutics, 452 (1–2), 344–354.
   PubMed Web of Science ®Google Scholar
• Yu, J., et al., 2020. Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy. Acta pharmaceutica sinica. B, 10 (9), 1730–1740.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2021. Brain-targeted delivery of obidoxime, using aptamer-modified liposomes, for detoxification of organophosphorus compounds. Journal of controlled release, 329, 1117–1128.
   PubMed Web of Science ®Google Scholar
• Zheng, X., et al., 2015. Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer's disease. Pharmaceutical research, 32 (12), 3837–3849.
   PubMed Web of Science ®Google Scholar
• Zhou, Y., et al., 2018. Crossing the blood-brain barrier with nanoparticles. Journal of controlled release, 270, 290–303.
   PubMed Web of Science ®Google Scholar